# Day One Biopharmaceuticals, Inc.: Phase 3 study closed enrollment, 418 enrolled (Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Day One Biopharmaceuticals, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) |
| NCT ID | NCT05566795 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Low-grade Glioma; Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma; Pediatric Low-grade Glioma |
| Intervention types | drug |
| Target enrollment | 418 |
| Site countries | United States, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, Egypt, Finland, France, Germany |
| Posted | 2022-10-04 |
| Planned start | 2023-02-27 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-19 |
| Last update posted | 2026-10-19 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 418 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05566795). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.